2020
DOI: 10.1016/j.bios.2020.112622
|View full text |Cite
|
Sign up to set email alerts
|

Detachable microfluidic device implemented with electrochemical aptasensor (DeMEA) for sequential analysis of cancerous exosomes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
43
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
6
1
1

Relationship

1
7

Authors

Journals

citations
Cited by 77 publications
(45 citation statements)
references
References 29 publications
0
43
0
Order By: Relevance
“…Selective quantification of biomarkers in nanovesicles derived from cancerous tissues was performed using microfluidics-based on liquid biopsy screening tests which improved the accuracy of the results [ 121 ]. Highly sensitive cancerous exosomes were quantified using a detachable microfluidic device implemented with electrochemical aptasensor (DeMEA) which helped in the early detection of cancerous biomarkers thereby contributing to the early diagnosis (exosome-based cancer diagnosis) [ 122 ]. A microfluidic device called ExoChip was designed to isolate and quantify circulating exosomes obtained directly from the serum sample of blood, which are a promising diagnostic biomarkers source and therefore, can be utilized for molecular screening of cancers [ 72 ].…”
Section: Methods Of Quantificationmentioning
confidence: 99%
“…Selective quantification of biomarkers in nanovesicles derived from cancerous tissues was performed using microfluidics-based on liquid biopsy screening tests which improved the accuracy of the results [ 121 ]. Highly sensitive cancerous exosomes were quantified using a detachable microfluidic device implemented with electrochemical aptasensor (DeMEA) which helped in the early detection of cancerous biomarkers thereby contributing to the early diagnosis (exosome-based cancer diagnosis) [ 122 ]. A microfluidic device called ExoChip was designed to isolate and quantify circulating exosomes obtained directly from the serum sample of blood, which are a promising diagnostic biomarkers source and therefore, can be utilized for molecular screening of cancers [ 72 ].…”
Section: Methods Of Quantificationmentioning
confidence: 99%
“…ADD may use better targets for its aptasensors beyond RBD S1 and hACE2. ADD can be accomplished, as suggested by the evidence from creation of DeMEA 158 (but it uses high cost microfluidics 159 ).…”
Section: Discussionmentioning
confidence: 99%
“…Based on the precise recognition of biomolecules, [ 68,79 ] subcellular organisms, [ 80 ] and cells, [ 71,81 ] the nanomaterial‐based biochemical sensors can be integrated with other devices (e.g., microfluidics and wearable devices) toward health management and therapeutic controlling systems. [ 82 ]…”
Section: Biomedical Applicationsmentioning
confidence: 99%